Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Clal Biotech ( (IL:CBI) ) has provided an update.
Clal Biotech has announced the completion of its divestment from Elicio Therapeutics, Inc., a Nasdaq-listed company. Furthermore, Clal Biotech has partially repaid a loan from Access, with $4.5 million already settled and an additional $5.1 million expected to be repaid by September 2025. This update reflects the company’s ongoing financial strategy and may impact its liquidity and future investment capabilities.
More about Clal Biotech
Clal Biotech operates in the biotechnology industry, focusing on investments in companies engaged in the development and commercialization of innovative therapeutic products.
YTD Price Performance: -4.18%
Average Trading Volume: 113,830
Current Market Cap: ILS54.74M
Learn more about CBI stock on TipRanks’ Stock Analysis page.